# Trial of Rifaximin in Probable Alzheimer's Disease

> **NCT03856359** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 10 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rifaximin 550 milligrams (MG)

## Key facts

- **NCT ID:** NCT03856359
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2020-11-19
- **Final completion:** 2020-11-19
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856359, "Trial of Rifaximin in Probable Alzheimer's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03856359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*